1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Glioblastoma Multiforme Market
2.2. Global Glioblastoma Multiforme Market, By Drug Type, 2024 (US$ Million)
2.3. Global Glioblastoma Multiforme Market, By Geography, 2024 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2024

3. Glioblastoma Multiforme Market: Competitive Analysis
3.1. Market Positioning of Key Glioblastoma Multiforme Market Vendors
3.2. Strategies Adopted by Glioblastoma Multiforme Market Vendors

4. Glioblastoma Multiforme Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Glioblastoma Multiforme Market Value, 2023 - 2033, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Technology Landscape
4.6.4. Legal Landscape
4.6.5. Social Landscape

5. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2024 Versus 2033
5.3. Market Segmentation
5.3.1. Temozolomide
5.3.2. Bevacizumab
5.3.3. Carmustine


6. North America Glioblastoma Multiforme Market, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
6.3.Glioblastoma Multiforme Market: By Region, 2023-2033, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)

7. UK and European Union Glioblastoma Multiforme Market, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
7.3.Glioblastoma Multiforme Market: By Region, 2023-2033, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
7.3.1.5. France
7.3.1.5.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)

8. Asia Pacific Glioblastoma Multiforme Market, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
8.3.Glioblastoma Multiforme Market: By Region, 2023-2033, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
8.3.1.3. India
8.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)

9. Latin America Glioblastoma Multiforme Market, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
9.3.Glioblastoma Multiforme Market: By Region, 2023-2033, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)

10. Middle East and Africa Glioblastoma Multiforme Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
10.3.Glioblastoma Multiforme Market: By Region, 2023-2033, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2023-2033, USD (Million)

11. Company Profile
11.1. AbbVie, Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Activartis GmbH
11.3. Agenus Inc.
11.4. Arog Pharmaceuticals, Inc.
11.5. Bristol-Myers Squibb Company
11.6. Cavion LLC
11.7. Celldex Therapeutics, Inc.
11.8. CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
11.9. Cortice Biosciences Inc.
11.10. Eisai Co., Ltd.
11.11. F. Hoffmann-La Roche Ltd.
11.12. Exelixis Inc.
11.13. Peregrine Pharmaceuticals, Inc.